Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$77.95MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- David Moatazedi
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 353
- Beta
- 1.34
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -1.37
Financials
Revenue
$77.95M+3273.1%Net Income
$-12.52MEBITDA
$-6.41MFree Cash Flow
$-2.25MEPS (diluted)
$-0.19Shares Outstanding (diluted)
66.09M+255.4%Operating Expenses
$55.94MCash & Debt
$41.70MReturn of Capital
$0.00Revenue by Segment (annual)
$297.18MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $297.18M | $-51.64M | $-0.80 |
| 2024 | $266.27M | $-50.42M | $-0.81 |
| 2023 | $202.09M | $-61.69M | $-1.08 |
| 2022 | $148.62M | $-74.41M | $-1.33 |
| 2021 | $99.67M | $-46.81M | $-0.94 |
| 2020 | $56.54M | $-163.01M | $-4.83 |
| 2019 | $34.92M | $-90.03M | $-3.19 |
| 2018 | $0.00 | $-46.87M | $-1.92 |
| 2017 | $0.00 | $-4.48M | $-0.19 |
| 2016 | $0.00 | $-20.07M | $-1.08 |
| 2015 | $0.00 | $-31.11M | $-1.67 |
Valuation
EOLShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-28.57%Social Signal Score
Mentions (10)
- Newsmarketbeat.com·7d ago·Neutral
Evolus Eyes 2027 Sculpt Launch as Filler Portfolio Expands and Revenue Grows Evolus NASDAQ: EOLS executives said the company expects its expanding lineup of injectable aesthetics products to support growth as it prepares for the anticipated launch of Evolysse Sculpt in 2027.
View source ↗ - Newsbusinesswire.com·9d ago·Negative
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during August 2026 to November 2026 of an aggregate of 194,335 restricted stock units (RSUs) of the company's common stock to 25 newly hired non-executive employees. The RSUs vest 25% on each anniversary of the vesting commencement …
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Evolus, Inc. (EOLS) Q3 2026 Earnings Call Transcript Evolus, Inc. (EOLS) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·18d ago·Neutral
What Evolus (EOLS) Said on Its Q3 Earnings Call Evolus NASDAQ: EOLS reported third-quarter revenue of $78 million, up 13% from a year earlier, as sales of its injectable products grew and the company posted its fourth consecutive quarter of positive adjusted EBITDA.
View source ↗ - Newszacks.com·18d ago·Neutral
Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates Evolus, Inc. (EOLS) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.14 per share a year ago.
View source ↗ - Newsbusinesswire.com·25d ago·Neutral
Evolus to Participate in Upcoming Investor Conferences in New York and London NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that members of its management team will participate in two upcoming investor conferences in New York and London: The Stifel Healthcare Conference, where management will participate in a fireside chat and host investor meetings on Wednesday…
View source ↗ - Newsbusinesswire.com·41d ago·Negative
EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $EOLS--EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law.
View source ↗ - Newsbenzinga.com·51d ago·Negative
Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug The U.S. Food and Drug Administration's Office of Prescription Drug Promotion in September issued a warning letter to Evolus Inc. (NASDAQ:EOLS) regarding misleading Instagram promotional posts for its injectable prescription drug, Jeuveau (prabotulinumtoxinA-xvfs).
View source ↗ - Newszacks.com·87d ago·Positive
Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet The mean of analysts' price targets for Evolus (EOLS) points to a 77.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗ - Newsseekingalpha.com·103d ago·Neutral
Evolus: The Injectable Platform Is Becoming The Real Moat Evolus is evolving into a multi-product aesthetics platform, leveraging its distribution network and loyalty ecosystem to drive operating leverage and recurring revenue. Q2 2026 results showed 21% revenue growth, positive adjusted EBITDA, and raised guidance, with management projecting 2028 revenue of $450M–$500M and EBITDA margins of 13–15%. Evolus trades at a forward EV/Sales of 1.86, a 50% discount to sector median, but requires margin
View source ↗
Earnings
Tue, Mar 2(in 3 months)
Consensus estimate $0.10 per share
Typical surprise -26.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$-0.09 vs $-0.06miss
- Wed, Aug 5$0.01 vs $-0.03beat
- Mon, May 4$-0.10 vs $-0.14beat
- Tue, Mar 3$0.04 vs $0.06miss
- Wed, Nov 5$-0.14 vs $-0.19beat
- Tue, Aug 5$-0.24 vs $-0.09miss
Estimates and results for EOLS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by EOLS officers and directors.
- Bought
- $393k
- Sold
- $14.8m
2 trades
41 trades
- Moatazedi Davidsold
- Avelar Ruisold
- Moatazedi Davidsold
- Moatazedi Davidsold
- Avelar Ruisold
- Moatazedi Davidsold
- Avelar Ruisold
- Yamagishi-dressler Tomokosold
57 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in EOLS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
